首页> 外文期刊>Romanian Journal of Diabetes Nutrition and Metabolic Diseases >Vildagliptin in the Treatment of Type 2 Diabetes Mellitus
【24h】

Vildagliptin in the Treatment of Type 2 Diabetes Mellitus

机译:维格列汀治疗2型糖尿病

获取原文
           

摘要

Novel therapeutic approaches are continuously being researched in type 2 diabetes. The incretin class of anti-diabetic agents, consisting of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors, has already found an important place in the current guidelines. Vildagliptin is a potent dipeptidyl peptidase-4 inhibitor, with numerous trials in type 2 diabetes treatment, both in monotherapy and in combination therapy. This review focuses on vildagliptin pharmacological properties, clinical efficacy and safety, and pharmacoeconomic data.
机译:在2型糖尿病中不断研究新的治疗方法。由胰高血糖素样肽1激动剂和二肽基肽酶4抑制剂组成的肠降血糖素类降血糖药已在当前指南中占据重要位置。维格列汀是一种有效的二肽基肽酶-4抑制剂,在单一疗法和联合疗法中均进行了许多2型糖尿病治疗试验。这篇综述着重于维格列汀的药理特性,临床疗效和安全性以及药物经济学数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号